Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
2012
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL
2010 StandoutNobel
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
2014 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
2013
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity
2010 StandoutNobel
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Acute lymphoblastic leukaemia
2008
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)
2010
Resistance to targeted therapy in renal-cell carcinoma
2009
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Renal cell carcinoma
2009
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs
2015
Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: A 15-year experience
2003
Sorafenib
2006
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
2007
The Crystal Structure of Archaeal Nascent Polypeptide-associated Complex (NAC) Reveals a Unique Fold and the Presence of a Ubiquitin-associated Domain
2005
Ten years of anti-vascular endothelial growth factor therapy
2016
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
2011
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
2009
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Structure of the Base of the L7/L12 Stalk of the Haloarcula marismortui Large Ribosomal Subunit: Analysis of L11 Movements
2007 StandoutNobel
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Gut microbiota modulation of chemotherapy efficacy and toxicity
2017 Standout
Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma
2011
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes
2009
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans
2009 Standout
A new patient‐focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options
2010
Photodynamic therapy of cancer: An update
2011 Standout
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Flying under the radar: the new wave of BCR–ABL inhibitors
2007
Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma
2013
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
2008
Defining the Intensity of Conditioning Regimens: Working Definitions
2009 Standout
Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy
2007
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
2013
Neutropenic enterocolitis in adults: systematic analysis of evidence quality
2005
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication
2018 Standout
Renal cell carcinoma
2017 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Combination targeted therapy in advanced renal cell carcinoma
2009
Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)
2013
PIP2: choreographer of actin-adaptor proteins in the HIV-1 dance
2014
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
The myth of the second remission of acute leukemia in the adult
2012
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
2012
Echinococcosis: Advances in the 21st Century
2019 Standout
Decision aids for people facing health treatment or screening decisions
2017 Standout
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Immunotherapy for renal cell cancer in the era of targeted therapy
2008
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
2018
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
2012
Cancer treatment and survivorship statistics, 2016
2016 Standout
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
2015
Cancer Drugs in the United States: Justum Pretium—The Just Price
2013
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
2016
Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient
2009
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
Targeted therapy for advanced renal cell carcinoma
2008
Works of Urban Scheuring being referenced
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
2009
Knockdown of ERM Family Member Moesin in Host Cells Increases HIV Type 1 Replication
2011
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment
2003
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
2002
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation
2001
Early modifications of host cell gene expression induced by HIV-1
1998
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
2005
Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination
2003
Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC)
2006
Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-α (IFN)
2008
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
2005
Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
2007
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
2003